TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BAX 855 (PEGylated Recombinant Factor VIII): A Phase 1, Prospective, Open Label, Cross-Over, Dose-Escalation Study in Previously Treated Patients (PTPs) With Severe (FVIII < 1%) Hemophilia A
Brief Summary: The objectives of this study are to assess the tolerability and safety after single dose treatments of BAX 855 in previously treated patients (PTPs) with severe hemophilia A, to determine the pharmacokinetic (PK) parameters of BAX 855 compared in crossover with ADVATE, and to evaluate the impact of anti-polyethylene glycol (PEG) antibodies on PK parameters.


Options:
A: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): On-demand
B: N/A
C: Arm Label: All participants; Type: EXPERIMENTAL; Interventions: Drug: BIIB031 (rFVIIIFc), Drug: FVIII (PK subgroup only) | Intervention Type: DRUG; Name: BIIB031 (rFVIIIFc); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: FVIII (PK subgroup only); Assigned to Arm(s): All participants
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Cohort 1, Cohort 2 | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Cohort 1, Cohort 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Brief Summary: A study to compare safety, tolerability, and immunogenicity of a new formulation of RotaTeq™ with the existing formulation in infants. The primary hypothesis of the study is that the new formulation will be noninferior to the existing formulation on the basis of immunogenicity.


Options:
A: Arm Label: RotaTeq™ Experimental Formulation; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq™ experimental formulation | Arm Label: RotaTeq™ Existing Formulation; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq™ existing formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ experimental formulation; Assigned to Arm(s): RotaTeq™ Experimental Formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ existing formulation; Assigned to Arm(s): RotaTeq™ Existing Formulation
B: Arm Label: Rotarix + No IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine), Biological: Rotarix | Arm Label: No Rotarix + No IPV (inactivated polio vaccine); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: IPV (inactivated polio vaccine); Assigned to Arm(s): No Rotarix + IPV (inactivated polio vaccine), Rotarix + IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix + IPV (inactivated polio vaccine), Rotarix + No IPV (inactivated polio vaccine)
C: Arm Label: Group 1: Concomitant Administration; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Arm Label: Group 2: Sequential Administration; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration | Intervention Type: BIOLOGICAL; Name: NeisVac-C®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration
D: Arm Label: PLACEBO-ROTARIX-ROTARIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: ROTARIX-PLACEBO-ROTARIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: PLACEBO GROUP; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): PLACEBO-ROTARIX-ROTARIX GROUP, ROTARIX-PLACEBO-ROTARIX GROUP | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): PLACEBO GROUP, PLACEBO-ROTARIX-ROTARIX GROUP, ROTARIX-PLACEBO-ROTARIX GROUP

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Brief Summary: A study to compare safety, tolerability, and immunogenicity of a new formulation of RotaTeq™ with the existing formulation in infants. The primary hypothesis of the study is that the new formulation will be noninferior to the existing formulation on the basis of immunogenicity.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus Vaccine (ROTARIX) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Rotavirus Vaccine (ROTARIX); Assigned to Arm(s): 1
B: Arm Label: HIV-uninfected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-uninfected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: HIV-infected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-1 infected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RotaTeq; Assigned to Arm(s): HIV-infected RotaTeq, HIV-uninfected RotaTeq | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): HIV-1 infected Placebo, HIV-uninfected Placebo
C: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
D: Arm Label: RotaTeq™ Experimental Formulation; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq™ experimental formulation | Arm Label: RotaTeq™ Existing Formulation; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq™ existing formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ experimental formulation; Assigned to Arm(s): RotaTeq™ Experimental Formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ existing formulation; Assigned to Arm(s): RotaTeq™ Existing Formulation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™
Brief Summary: A study to compare safety, tolerability, and immunogenicity of a new formulation of RotaTeq™ with the existing formulation in infants. The primary hypothesis of the study is that the new formulation will be noninferior to the existing formulation on the basis of immunogenicity.


Options:
A: Arm Label: RotaTeq™ Experimental Formulation; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq™ experimental formulation | Arm Label: RotaTeq™ Existing Formulation; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq™ existing formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ experimental formulation; Assigned to Arm(s): RotaTeq™ Experimental Formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ existing formulation; Assigned to Arm(s): RotaTeq™ Existing Formulation
B: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Rotarix, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
C: Arm Label: HIV-uninfected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-uninfected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: HIV-infected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-1 infected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RotaTeq; Assigned to Arm(s): HIV-infected RotaTeq, HIV-uninfected RotaTeq | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): HIV-1 infected Placebo, HIV-uninfected Placebo
D: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Visual Cue Training to Improve Walking and Turning After Stroke: a Pilot Study
Brief Summary: Given that visual information comprises one of the most important and salient sources of information used during walking, that visual cues have been shown to be more effective than auditory cues in triggering gait adjustments and that stroke survivors have been reported to become more dependent on visual cues, the investigators hypothesize that visual cues would be more effective in triggering gait recovery and adaptability following stroke than interventions not including visual cues.

The investigators will integrate visual cues with walking and turning practice, and contrast this intervention to routine overground walking practice. Stroke participants recruited from NHS stroke rehabilitation clinics in the West Midlands, will be randomized to one of three gait rehabilitation groups. Each group will receive the same frequency and duration of treatment delivered by qualified physiotherapists. Overground visual cue training (OVCT) and usual care (UC) groups will be treated in participating NHS sites. Treadmill training with visual cues (TVCT) will take place at the University of Birmingham.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: Low Vision Intervention - Outpatient Training Program | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Low Vision Intervention - Outpatient Training Program; Assigned to Arm(s): Arm 1
B: Arm Label: regular O&M-training; Type: ACTIVE_COMPARATOR; Interventions: Other: orientation and mobility training | Arm Label: standardised O&M-training; Type: EXPERIMENTAL; Interventions: Other: orientation and mobility training | Intervention Type: OTHER; Name: orientation and mobility training; Assigned to Arm(s): regular O&M-training, standardised O&M-training
C: Arm Label: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga Intervention | Intervention Type: BEHAVIORAL; Name: Yoga Intervention; Assigned to Arm(s): Yoga Therapy
D: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Overground visual cue training; Type: EXPERIMENTAL; Interventions: Behavioral: Overground visual cue training | Arm Label: Treadmill visual cue training; Type: EXPERIMENTAL; Interventions: Behavioral: Treadmill visual cue training | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care | Intervention Type: BEHAVIORAL; Name: Overground visual cue training; Assigned to Arm(s): Overground visual cue training | Intervention Type: BEHAVIORAL; Name: Treadmill visual cue training; Assigned to Arm(s): Treadmill visual cue training

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Vitamin D Supplementation for Prevention of Respiratory Morbidity in Extremely Preterm Infants: A Randomized Clinical Trial
Brief Summary: The study hypothesis states that giving early enteral Vitamin D supplementation to preterm infants will decrease respiratory morbidity in extremely preterm infants.


Options:
A: Arm Label: Oral Vitamin D--200 IU/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Oral Vitamin D--800 IU/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Oral Vitamin D--200 IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Oral Vitamin D--800 IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Devit-3 Oral Drop 400 IU; Type: OTHER; Interventions: Drug: Devit-3 Oral Drop | Arm Label: Devit-3 Oral Drop 800 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Devit-3 Oral Drop | Arm Label: Devit-3 Oral Drop 1000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Devit-3 Oral Drop | Intervention Type: DRUG; Name: Devit-3 Oral Drop; Assigned to Arm(s): Devit-3 Oral Drop 1000 IU, Devit-3 Oral Drop 400 IU, Devit-3 Oral Drop 800 IU
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D, cholecalciferol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D, cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D, cholecalciferol; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D, cholecalciferol; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
Brief Summary: Postpartum hemorrhage (PPH) is the leading cause of maternal death worldwide, with an estimated mortality of 140 000 per year. Uterine atony is one of the most important causes of PPH. The traditional treatment of which is the use of uterotonic agents. Oxytocin is the most conventional drug which was proved effective. However, it has the shortcomings of short half life and the necessity of intravenous administration. Misopristol, and more recently Carbetocin were introduced for treatment of atonic PPP not responding to Oxytocin.

Aim of the study is to evaluate the effectiveness of Carbetocin, Misopristol, and Oxytocin for treatment of atonic PPH.


Options:
A: Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxytocin | Arm Label: carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: carbetocin | Arm Label: misopristol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misopristol | Intervention Type: DRUG; Name: carbetocin; Assigned to Arm(s): carbetocin | Intervention Type: DRUG; Name: misopristol; Assigned to Arm(s): misopristol | Intervention Type: DRUG; Name: oxytocin; Assigned to Arm(s): Oxytocin
B: Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol
C: Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
D: Arm Label: Ergometrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ergometrine | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Ergometrine; Assigned to Arm(s): Ergometrine | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Italian Diabetes and Exercise Study 2 - A Long-term Behavioural Intervention for Adoption and Maintenance of a Physically Active Lifestyle
Brief Summary: Current guidelines recommend supervised mixed (aerobic+resistance) physical activity to ensure optimal benefits to control blood glucose, lipids, blood pressure, and other cardiovascular risk and to minimize injuries. However, these guidelines are difficult to put into action for a number of barriers and poor long-term patient compliance. This project will assess the effect of a behavioral intervention strategy on the promotion and maintenance of physical activity in type 2 diabetes.


Options:
A: Arm Label: High Volume; Type: ACTIVE_COMPARATOR; Interventions: Other: High Volume | Arm Label: Moderate Volume; Type: ACTIVE_COMPARATOR; Interventions: Other: Moderate Volume | Intervention Type: OTHER; Name: Moderate Volume; Assigned to Arm(s): Moderate Volume | Intervention Type: OTHER; Name: High Volume; Assigned to Arm(s): High Volume
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Theoretical & practical exercise counseling | Intervention Type: BEHAVIORAL; Name: Theoretical & practical exercise counseling; Assigned to Arm(s): Exercise
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intervention | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: No intervention; Assigned to Arm(s): Control
D: Arm Label: Behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral intervention to reduce sedentary time delivered via mobile smartphone | Intervention Type: BEHAVIORAL; Name: Behavioral intervention to reduce sedentary time delivered via mobile smartphone; Assigned to Arm(s): Behavioral intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Two Injection Techniques Added to Proven Strategies to Reduce Pain in One- to Twelve-month Old Infants Undergoing Immunization
Brief Summary: Immunization injections are a significant source of pain for infants. Tactile stimulation (rubbing/applying pressure) may be an effective and feasible pain-relieving intervention - it is cost neutral, and has been shown to be effective in children and adults undergoing injections. The aim of this study is to determine the added benefit of tactile stimulation when added to other proven analgesic interventions during routine infant immunization injections.


Options:
A: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Educational Video - Sham, Drug: Sucrose Placebo (water), Drug: Lidocaine Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose Placebo (water), Drug: Lidocaine Placebo | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose, Drug: Lidocaine Placebo | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose, Drug: Lidocaine | Intervention Type: BEHAVIORAL; Name: Educational video - Active; Assigned to Arm(s): Group 2, Group 3, Group 4 | Intervention Type: BEHAVIORAL; Name: Educational Video - Sham; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Sucrose Placebo (water); Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: Lidocaine Placebo; Assigned to Arm(s): Group 1, Group 2, Group 3 | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Group 4
B: N/A
C: Arm Label: Pentacel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pentacel (DPTaP+Hib) | Arm Label: Prevnar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prevnar (conjugated pneumococcal vaccine) | Intervention Type: DRUG; Name: Pentacel (DPTaP+Hib); Assigned to Arm(s): Pentacel | Intervention Type: DRUG; Name: Prevnar (conjugated pneumococcal vaccine); Assigned to Arm(s): Prevnar
D: Arm Label: Tactile stimulation; Type: EXPERIMENTAL; Interventions: Behavioral: Tactile stimulation | Arm Label: No tactile stimulation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tactile stimulation; Assigned to Arm(s): Tactile stimulation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease
Brief Summary: The purpose of this study is to evaluate the effects of HQK-1001 on Hb F in subjects with sickle cell disease.


Options:
A: Arm Label: thalidomide thalassemia; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): thalidomide thalassemia
B: Arm Label: HQK-1001; Type: ACTIVE_COMPARATOR; Interventions: Drug: HQK-1001 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HQK-1001; Assigned to Arm(s): HQK-1001 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: thalidomide thalassemia; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): thalidomide thalassemia
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Decitabine (USAN, INN) | Intervention Type: DRUG; Name: Decitabine (USAN, INN); Assigned to Arm(s): 1

Answer: B